Industry News

Three biopharma developers, including the Institute of Science Tokyo, selected the CDMO’s Yokohama site for cell therapy process development and manufacturing support.
Nov. 17, 2026
The agreement gives the Hong Kong-based pharmaceutical company exclusive rights to use the TfR1 platform in up to two neurodegenerative disease programs.
Nov. 17, 2026
The acquisition of the Chemistry, Manufacturing and Controls team adds more than 35 specialists in biologics development, production oversight, and regulatory strategy.
Nov. 16, 2026
The CDMO will produce an AAV2 vector and plasmids for IND-enabling studies and a planned Phase 1/2 trial of Celliaz’s investigational therapy.
Nov. 16, 2026
The agreement establishes dedicated manufacturing capacity and supply chain controls for consumables used in Ori’s automated cell therapy manufacturing platform.
Nov. 13, 2026
A Swedish government agency awarded Mendus about $100,000 to establish a donor-derived cell manufacturing platform using a technology that stimulates NK cell expansion.
Nov. 13, 2026
The new Lipid Innovation Center will manufacture pharmaceutical lipids for RNA medicines and other advanced therapies, with full production capacity expected by mid-2027.
Nov. 12, 2026
The expanded authorization allows the German CDMO to manufacture sterile viral drug substances and investigational medicinal products, including advanced therapies.
Nov. 12, 2026
The 153,000-square-foot facility adds prefilled syringe, vial, and lyophilization capacity at the company’s Bloomington site.
Nov. 11, 2026

Looking for Something?